a Department of Psychiatry , University of Pennsylvania Perelman School of Medicine , Philadelphia , PA , USA.
b National Center for Natural Product Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy , University of Mississippi , University , MS , USA.
Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.
Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical development. This commentary discusses the unique challenges and merits of botanical vs single molecule cannabinoid drug development strategies, highlights how both can be impacted by legalization of cannabis via legislative processes, and also addresses regulatory and public health considerations that are important to consider as cannabinoid medicine advances as a discipline.
越来越多的证据表明，内源性大麻素系统是治疗多种健康状况的有前途的靶点。大麻素药物开发有两种途径。一种方法是专注于开发直接从大麻植物中提取的药物。另一种方法是采用单分子方法，即鉴定和合成具有治疗潜力的单一植物大麻素或新型大麻素，以进行药物开发。本评论讨论了植物大麻素与单分子大麻素药物开发策略的独特挑战和优点，强调了立法过程中通过大麻合法化如何影响这两种策略，还讨论了在大麻素药物作为一门学科发展过程中需要考虑的监管和公共卫生方面的考虑因素。
